



VLADYSLAV SUKHIN

Ukraine

Personal statement

I have passed a long accumulating practical and scientific knowledge in Oncogynecology from the beginning, so as gaining experience, being National representative of ENYGO in Ukraine. My activity in Ukrainian society of Oncogynecology, so as opportunity to act as a Vice-President of ENYGO, has given administrative experience. I bring to the ESGO Council a strong foundation in field of Oncogynecology, combined with a deep commitment to advancing collaborative, ethical, and impactful science.

My academic and professional background has equipped me with the critical thinking, analytical skills, and interdisciplinary perspective necessary to contribute meaningfully to ESGO mission of promoting scientific excellence and addressing complex global challenges.

Throughout my career, I have consistently sought opportunities to bridge research with real-world application. Whether through the lead of the research projects or acting as principal investigator in national and international study projects, mentoring early-career scientists, or engaging in science communication, I have worked to ensure that science remains inclusive, transparent, and responsive to societal needs. These values align closely with the ESGO goals of fostering innovation, diversity, and public trust in science.

One of my key strengths is strategic thinking - particularly in identifying emerging trends and fostering environments that encourage innovation and integrity. I am motivated by the opportunity to help shape the direction of scientific inquiry and policy, ensuring that research remains relevant, equitable, and responsible.

I also bring experience in governance and committee work, which has strengthened my ability to collaborate effectively, manage differing viewpoints, and uphold high standards of decision-making.

My motivation to join ESGO Council stems from a desire to serve the scientific community at a broader level, contributing to strategic initiatives, supporting the next generation of scientists, and reinforcing the societal value of science. I am especially passionate about promoting interdisciplinary collaboration and widening participation, both of which are critical to addressing today's scientific and societal challenges. In summary, I offer a balanced blend of research experience, leadership skills, and a principled commitment to the values that underpin the ESGO mission. I would be honored to support and advance its goals as a member of the ESGO Council.

EUROPEAN
CURRICULUM
VITAE
FORMAT



PERSONAL INFORMATION

Name	Vladyslav S. SUKHIN
Address	82, HRYHORIA SKOVORODY STR., 61024 KHARKIV, UKRAINE
Telephone	+380-95-8816458 mobile
Fax	+380-57-7255073
E-mail	suhin_vlad@ukr.net
Nationality	Ukraine
Date of birth	02. Nov. 1979

WORK EXPERIENCE

• Dates (from – to)	FEB 2004 – TILL NOW	OCT 1999 – JAN 2004
• Name and address of employer	Grigoriev Institute of Medical Radiology & Oncology, NAMS of Ukraine	Institute of Medical Radiology, NAMS of Ukraine
	Dept. of Oncogynecology	Radiation therapy dept., nurse
• Occupation or position held	Oncogynecologist, Senior Clinical Researcher	
• Main activities and responsibilities	Research work, patients' treatment	
	(since June.2019 – Lead clinical researcher, since 2022 - Professor)	
	Sept.2022 – Sept.2023	University hospital LKH-Graz, gynecological clinic, Pandemic physician

Academic work
experience

2009 - 2010 **Professor assistant**, chair of Oncology, Kharkov National medical University

2010 – 2013 **Professor associate**, chair of Gynecology and Radiology, Medical faculty, V.N. Karazin National University

2013 - 2019 **Professor associate**, chair of Surgery (Radiology), Medical faculty, V.N. Karazin National University

2019 – 2021 **Professor associate**, chair of Oncology and Radiology, Medical faculty, V.N. Karazin National University

2021 - 2022 **Professor**, chair of Oncology and Oncology of childhood age, Kharkiv medical academy for postgraduate education

2022 – 2022 **Professor**, chair of Oncology, Radiology and radiation medicine, Medical faculty, V.N. Karazin National University, Kharkiv

2016 – 2021 **Expert, Member of Expert council of the Ministry of education and science of Ukraine**

EDUCATION

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupation

Postgraduate Specialization course

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills
- Title of qualification awarded

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills
- Title of qualification awarded

Postgraduate Education – Training update

1996 – 2002

Kharkov State Medical University

General medicine, Physician (*diploma with honors*)

1986 – 1996

Secondary school

1 2002-2004

Kharkov Regional Hospital,
Kharkov National medical University

(*Internship*)

Obstetrics and Gynecology

Gynecologist, specialist

2. 03-04.2004

Kharkov medical Academy of
Postgraduate Education (KhMAPE)

**Diagnostic and treatment of
women's genital cancer.**

3. 02-07.2006

Kiev medical Academy for
Postgraduate Education

Radiation therapy

Radiation therapist, specialist

4. 01-04.2007

Kharkov medical Academy for
Postgraduate Education

Gynecological Oncology

Gynecological Oncologist, specialist

01.-02.2019

Kharkov medical Academy for.
Postgraduate Education

Management in healthcare

Specialist

02. – 06.2020

Kharkov medical Academy for
Postgraduate Education

Clinical Oncology

Clinical Oncologist, specialist

2004 (1 month) Diagnostic and treatment of women's genital cancer, (KhMAPE)

2004 (1 month) Clinical parasitology, (KhMAPE)

2007 (1 month) Extragenital pathology in obstetrics and gynecology, (KhMAPE)

2008 (1 month) Sexually transmitted infections, (KhMAPE)

2008 (1 month) Dermatoooncology, (KhMAPE)

2008 (1 month) Oncogynecology, (KhMAPE)

2009 (1 month) Pain syndrome and methods of its care, (KhMAPE)

2009 (1,5 month) Some aspects of radiation therapy and radionuclide diagnostic of different tumors, (KMAPE)

2009 (1,5 month) Children and adolescent gynecology

2010 (1 month) Dermatoooncology, (KhMAPE)

2010 (1 month) Oncogynecology, (KhMAPE)

2011 (1 month) Diagnostic and treatment of women's genital cancer, (KhMAPE)

2011 (1 month) Radiation therapy, clinical training, (KMAPE)

2012 (1 month) Ukrainian language for professionals, (KhMAPE)

2012-2013 (15 months) Oncosurgery, oncogynecology, intensive care in oncology (IMRO)

2014 (2 weeks) Uptodate in clinical haemostasiology, (KhMAPE)

2014 (1,5 month) Up-to-date radiation therapy and radionuclide diagnostic of different tumors, (KMAPE)

2015 (1 month) Oncogynecology, (KhMAPE)

2017 (1 month) HIV-infections, voluntarily consultation, (KhMAPE)

2017 (5 weeks) Radiation therapy, clinical training, (KMAPE)
 2018 (1 month) Immune-histochemical investigation in diagnostic of neoplasms and other disease, (KhMAPE)
 2018 (1 month) The main principles of cancer diagnosis in women, (KhMAPE)
 2019 (2 months) Organisation and Management in healthcare system, (KhMAPE)
 2021 (2 weeks) Basic training in endoscopic surgery, (KhMAPE)

Additional education	09.2019 – 12.2020 V.N. Karazin National University <i>Administrative management</i>	09.-12.2021 Admiral Makarov National University of Shipbuilding, <i>Management in healthcare Master's Degree</i>
Nostrification education	12.2022 – 06.2023 Graz medical University, Education program for medical University Diplom nostrification, obtained degree « <i>Doctor medicinae universae</i> » (<i>Dr.med.Univ.</i>)	
PH.D. STUDY	2006 – 2010, research project: « <i>Preoperative chemo-irradiation in treatment of cervical cancer patients</i> »	
Doctor of med. Science Academic degree (Habilitation)	2013 – 2018, research project: «<i>Principles and justification of the individualization of uterine sarcoma treatment</i>» approved in 2019 (Kiev, Ukraine). Senior clinical researcher (Dozent) approved in 2015 (Kiev, Ukraine). Doctor of medical science (DSc), approved in 2019 (Kiev, Ukraine). University Professor, approved in Aug. 2022 (Kiev, Ukraine). Dr. med. Univ. (Austria), May 2023.	
STIPEND/ GRANT	• DAAD-STIPEND (GRANT) for young scientists (3 month), 2007 • Stipend of Government of Ukraine for young scientists, 2008-2009	
Awards	16.06.2021 obtained <i>Award of Cabinet of Ministers of Ukraine</i> for the developments and implementation of innovative technologies in medicine.	
Conference organization experience	2010 - 2015 – <i>responsible organizer</i> for the conference of young scientists of Grigoriev Institute for medical Radiology. May 2013 - <i>responsible organizer</i> for the conference of Association of young scientists of the Institutes of National academy of medical science in Ukraine, and satellite symposium with ESGO/ENYGO endorsement «<i>Uterine sarcoma</i>». 2013 – 2017 – <i>co-organizer of ENYGO seminars</i> May 2016 - <i>co-organizer of National congress of Oncologists and Radiologists, Kiev, Ukraine</i> April 2018 – ESGO supported meeting “<i>Minimal invasive approach in oncosurgery and oncogynecology</i>”, <i>responsible organizer, Kharkov</i> October 2019 – <i>responsible organizer, Conference "Current and perspective directions in clinical oncology", Kharkov</i> October 2021 – <i>co-organizer, XIV National Congress of oncologist and radiologists of Ukraine, Kiev</i>	

Clinical trials experience

Principle investigator / Co-investigator -

An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting. PALO-10-01 [NCT01363479](#).

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting. NETU-10-29 [NCT01376297](#).

*A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as **First-line** Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer, NCT03602859, (2018 - ongoing),*

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non- mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43) MK-7339-001, [NCT03740165](#), (2018 - ongoing),

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001), [NCT03884101](#), (2019 - ongoing),

*A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (**RUBY**), NCT03981796, (2019 - ongoing),*

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression, NCT04209855, (2019 - ongoing),

*A Single-arm Phase II Trial to Evaluate the Safety and Efficacy of the Antibody-Drug Conjugate (ADC) **SYD985** in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Endometrial Carcinoma Who Previously Progressed on or After First Line Platinum-based Chemotherapy, NCT04205630, (2019 - ongoing),*

*A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced **Cervical Cancer** (KEYNOTE-A18/ENGOT-cx11/GOG-3047), NCT04221945, (2020 - ongoing),*

*A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-**B21** / ENGOT-en11 / GOG-3053), NCT04634877, (2021 - ongoing).*

VulCan, SarcUt (Spain, La Paz),

***SUCCOR** – An International European Retrospective Cohort Observational Study Comparing Laparoscopic or Robotic Radical Hysterectomy Versus Abdominal Radical Hysterectomy in Patients With Stage IB1 (FIGO 2009) Cervical Cancer Operated in 2013-2014. [NCT03958305](#).*

***RACE**: international, multicentric, retrospective study on rare types of cervical cancer (CEEGOG CX-06)*

***ENGOT-EN16/NOGGO S22/EXPRESSION XI: IMPROVE** - International Survey for Patients with EndoMetrial Cancer: **PeRspectiVe** and **Expectation** of Therapy and Quality of Life. [DRKS00025954](#)*

Academic international study

Academic national study participation (conducted in Grigoriev Institute of Medical Radiology & Oncology, NAMS of Ukraine)

Development of the methodic of preoperative chemo-radiation therapy course in treatment of cervical cancer patients.

Development of the methodic of the neoadjuvant chemotherapy in ovarian cancer patients.

Investigation of the prognostic serum and molecular markers in ovarian cancer.

Investigation of molecular markers in uterine sarcoma.

Investigation of circadian rhythms in patients with gynecological malignancy.

Investigation of the technology of immune correction during the radiation therapy.

Investigation of the methods of the improvement of treatment results in uterine cancer patients.

Investigation of methodology of the supportive treatment in cancer patients.

Development of the immune-correction therapy for patients with gynecological malignancy.

About 200 publications

<https://orcid.org/0000-0002-4403-3707>

<https://scholar.google.com/citations?hl=ru&user=eWpECWwAAAAJ>

https://www.researchgate.net/profile/Vladyslav_Sukhin

Web of science Researcher ID M-5297-2018

SCOPUS ID 57193517497

List of publications (attached)

Society Membership

- European society of Gynecological Oncology (**ESGO**)
- European Network of young gynecological oncologists (**ENYGO**) **Executive group member** (2013-2015) and **National Representative of Ukraine** (2007-2015), **ENYGO Vice-President** (2015-2017)
- European society of Medical Oncology (**ESMO**)
- International Gynecological cancer society (**IGCS**)
- Ukrainian society of Oncologists
- Ukrainian association of Oncogynecologists
- European Association for Endoscopic Surgery (**EAES**)

List of publications

N	Name of paper	Type of publication (journal, abstract book, etc.)	N. of pages	Co-authors
1.	The unitary preoperative irradiation application at radical surgical treatment for breast cancer on the initial stages.	10 th International Scientific Students' Conference, Gdansk, Poland, 9-11 May 2002, Abstract book, p.60.	1	V. Sukhin, V. Nomerovchenko, I. Sakomornaja
2.	The efficiency of local irradiation of the breast cancer with the usage of conservative operations.	13 th European Students' Conference 2002, Berlin, Germany. Abstract book, p.241.	1	V. Sukhin,
3.	The influence of local irradiation of the breast cancer to the efficiency of combined treatment with the usage of conservative operations.	1 st Students' Scientific Conference, Oslo, Norway, May 2002, Abstract book, p.20.	1	V. Sukhin, I. Sakomornaja
4.	The immune status in patients with cancer corporis uteri during the combination therapy.	14 th European Students' Conference 2003, Berlin, Germany. Abstract book, p.480.	1	V. Sukhin, N. Prohach
5.	Dynamic of the level of tumor-marker SCCA (squamous-cell carcinoma antigen) in different variants of cervical carcinoma treatment.	66 th Scientific Conference for students&young Scientists, Lvov, Ukraine. Apr. 2005. Abstract book. - p.79.	1	V. Sukhin, V. Hertman
6.	Sisters' chromatide exchange in lymphocytes of peripheral blood of patients with endometrial cancer after irradiation.	Scientific Conference for young scientists «Actual problems of radiation medicine and radiobiology». Kyiv, Ukraine, May 2005. Abstract book. p.34.	1	A. Schegolkov, N. Masnik, A. Ircha. A. Mihanovskij V. Sukhin
7.	An experience of the use of a new marker of squamous-cell tumors SCC for monitoring cervical treatment.	Ukr Journ Radiology. – 2005; 3(Vol. XIII): 410-2.	3	O. Sukhina, A. Mihanovskij, V. Sukhin, S. Revenkova, V. Hertman, I. Krugovaja
8.	Analysis of different variants of combined treatment patients with endometrial cancer.	Conference for young Scientists “Medicine of the 3d century”, Jan.2006, Kharkov, Ukraine, Abstract book, p. 131-132.	2	O. Slobodjanjuk, N. Schit, V. Sukhin
9.	The possibility of the usage of tumor-marker SCCa for diagnosing the lymphatic node involvement in patients with cervical cancer at an early stage.	XI Congress of oncologist of Ukraine. May 2006. Sudak, Ukraine. Abstract book, p. 196-197.	2	O. Sukhina, A. Mihanovskij, V. Hertman, V. Sukhin, H. Kononenko, I. Krugovaja
10.	Results of combined treatment of patients with endometrial cancer using the preoperative irradiation with radio modification.	XI Congress of oncologist of Ukraine. May 2006. Sudak, Ukraine. Abstract book, p. 189.	1	A. Mihanovskij, O. Slobodjanjuk, L. Skripnik, O. Kasmiruk, N. Schit, I. Krugovaja, V. Sukhin

11.	Application of tumor marker SCCA in prognosis of lymphatic nodes involvement in patients with cervical cancer.	Ukr Journ Radiology. – 2006; 2 (Vol. XIV):162-5.	4	O. Sukhina, A. Mihanovskij, V. Sukhin, V. Hertman, I. Krugovaja
12.	Comparative analysis of efficacy of different programs of combined treatment of patients with cervical cancer.	Rad diagnostic, rad therapy - 2006; 2:71-4.	4	O. Sukhina, A. Mihanovskij, V. Sukhin, I. Krugovaja
13.	Radiochemotherapy in a palliative treatment of hepatic metastasis in oncological patients.	IV Congress of oncologists and radiologists of UIS. Baku, Azerbajdzhan. 28.09-01.10.06, Abstract book, p.237.	1	O. Sukhina, L. Zabobonina, A. Svinarenko, A. Mihanovskij, V. Sukhin
14.	Comparative analysis of combined treatment of patients with endometrial cancer, with or without radiomodification in preoperative irradiation.	IV Congress of oncologists and radiologists of UIS. Baku, Azerbajdzhan. 28.09-01.10.06, Abstract book, p. 229.	1	A. Mihanovskij, O. Sukhina, O. Slobodjanjuk, L. Skripnik, O. Kasmiruk, N. Schit, I. Krugovaja, V. Sukhin
15.	Comparative analysis of treatment outcome of patients with locally-advanced cervical cancer, treated by chemoradiation therapy.	Ukr Journ Radiology. – 2006; 3 (Vol. XIV):355-8.	4	O. Sukhina, O. Nermalzova, A. Mihanovskij, A. Svinarenko, V. Sukhin, I. Krugovaja
16.	Assessment of the efficacy of combined treatment for endometrial cancer with or without preoperative distant radiation therapy.	Ukr Journ Radiology. – 2006; 4 (Vol. XIV):423-6.	4	A. Mihanovskij, O. Slobodjanjuk, L. Skripnik, I. Krugovaja, N. Schit, O. Kasmiruk, V. Sukhin
17.	Case-report of multiple synchronal involvement of genitals by benign tumor.	Ukr Journ Radiology. – 2007; 1 (Vol. XV):76-7.	2	I. Krugovaja, A. Mihanovskij, O. Slobodjanjuk, L. Skripnik, N. Schit, V. Sukhin, N. Fedorenko
18.	Assessment of the efficacy of combined treatment for cervical cancer using preoperative chemoradiotherapy.	Ukr Journ Radiology. – 2007; 2 (Vol. XV):199-200. Abstr book meeting UTTRO	2	V. Sukhin, I. Krugovaja, L. Skripnik, O. Slobodjanjuk
19.	Interferons in treatment of cervical cancer.	«Medicine today and tomorrow» – 2007; 3: 135-41.	7	P. Sorochan, N. Prohach, O. Sukhina, I. Gromakova, V. Sukhin
20.	Evaluation of the efficiency of combined treatment with application of preoperative chemoirradiation in cervical cancer patients.	15 th International meeting of the European society of Gynaecological Oncology. Berlin, Germany. 28.10-01.11.07. Abstract book.	1	V. Sukhin, A. Mihanovskij, O. Sukhina, I. Krugovaja

21.	Self-descriptiveness of new marker SCCA in monitoring of treatment of cervical cancer patients.	V Congress of oncologists and radiologists of UIS. Tashkent, Uzbekistan. 14-16.05.08, Abstract book, p.130-1.	2	V. Sukhin, A. Mihanovskij, V. Hertman, I. Krugovaja, N. Schit, O. Slobodjanjuk
22.	Clinical characteristics and treatment efficacy in patients with stage IA-IIA, IIIB squamous cell uterine cervix carcinoma.	Ukr Journ Radiology. – 2008;2 (Vol.XVI):158-62.	5	A. Mihanovskij, V. Sukhin
23.	Clinical features of adenocarcinoma and treatment efficacy in cervical cancer patients.	Rad diagnostic, radiotherapy - 2008;3-4: 51-4.	4	A. Mihanovskij, V. Sukhin
24.	Comparative analysis of treatment efficacy in cervical cancer patients, depending on histological type of the tumor.	Ukr Journ Radiology. – 2008; 3 (Vol.XVI): 353-8.	6	V. Sukhin, A. Mihanovskij
25.	Ovarian metastasis of cervical cancer.	Oncology. – 2008; 3 (Vol. 10):374-376.	3	V. Sukhin,
26.	Ultrastructure of squamous-cell cervical cancer after chronomodulated radiochemotherapy.	Ukrainian Journ Radiol. – 2008; 4 (Vol. XVI): 397-402.	6	O. Lukashova, O. Sukhina, J. Nemaltsova I. Krugovaja, V. Sukhin, L. Sabobonina
27.	Tumor marker SCCA in the monitoring of treatment of cervical cancer.	Oncology. – 2009;1 (Vol. 11): 50-4.	5	V. Sukhin
28.	Peculiarities of squamous cell cervical cancer ultrastructure after different protocols of preoperative chemoradiation therapy.	Ukrainian Journal of Radiology. – 2009; 1 (Vol. XVII): 43-9.	7	O. Lukashova, V. Sukhin, A. Mihanovskij, I. Krugovaja, I. Teslenko
29.	Echsonographic control of the cervical tumor response to preoperative chemoradiation therapy.	Ukrainian Journal of Radiology. – 2009; 2 (Vol. XVII): 163-7.	5	V. Sukhin
30.	The role of new tumor-marker SCCA in diagnostic and treatment of cervical cancer.	Scientific Conference for students&young Scientists «Modern aspects of medicine and pharmacy-2009». Zaporozhje, Ukraine. May. 2009. Abstract book. -p.59.	1	M. Teplova A. Mihanovskij, V. Sukhin
31.	Efficacy analyse of preoperative chemoradiation therapy in cervical cancer patients.	16 th Int meeting of the Eur society of Gyn Oncol. Belgrade, Serbia. 11-14.10.09. Abstract book, p. 573.	1	V. Sukhin, O. Slobodyanyuk, N. Schit, A. Granovskaya, N. Fedorenko
32.	Training in Gynaecology Oncology Across Europe.	Textbook of gyn. oncology. Gunes Publ.- 2009. Section XV. P.620-1.	2	V. Sukhin

33.	The method of combined treatment of cervical cancer.	Patent №44541 UA, MPK A61N5/10. pub. 12.10.09	4	A.Mihanovskij, V. Sukhin, I. Krugovaja, V. Hertman
34.	Efficacy analyse of combined treatment of endometrial cancer patients with preoperative cryo-radiation therapy.	Journ «Surgical perspectives» - 2010: 2; 75-7.	3	A. Mihanovskij, O. Slobodjanjuk, I. Krugovaja, N. Schit, N. Fedorenko, V. Sukhin
35.	Chronomodulated regimen of radiochemotherapy as a method of toxicity decrease at antitumor treatment of neoplasms.	Int conference «Radiological and ecological security of people and environment: situation and methods of perfection». Jalta, Ukraine. -06.2010. Abstr. book, - p.46-7.	2	Sukhina O.N., Svinarenko A.V., Starenkij V.P., V. Sukhin, Granovskaja A.I.
36.	Chronomodulated regimen of radiochemotherapy as a method of toxicity decrease at antitumor treatment of neoplasms.	Scientific works Journ. Series: «Technogenic safety». -2010. -Ed. 126(139). -p.31-6.	6	Sukhina O.N., Svinarenko A.V., Starenkij V.P., V. Sukhin, Granovskaja A.I.
37.	Prognostic value of the tumor marker SCCA in the monitoring of cervical cancer patients.	13 th meeting of the Int Gyn cancer society. Prague, Czech Republic. 10.2010. Abstract book, p. 410.	1	V. Sukhin, V. Hertman, E. Sukhina, I. Krugovaja
38.	Advisability of chemoradiotherapy at cervical cancer treatment.	Ukrainian Journal of Radiology. - 2011;1(19): 73-8.	6	Sukhina O. N., Starenkij V.P., Svinarenko A.V., Sukhin V., Granovskaja A.I.
39.	Gynecologic Oncology Training Systems in Europe: A Report From the European Network of Young Gynaecological Oncologists.	Int J Gynecol Cancer -2011;21: 1500-06. doi: 10.1097/IGC.0b013e3182202d17 http://www.ncbi.nlm.nih.gov/pubmed/21720256	2	Gultekin M, Dursun P, Vranes B, Laky R, Bossart M, Grabowski JP, Piek JM, Manchanda R, Grimm C, Dallaku K, Babloyan S, Moisei A, Van Gorp T, Cadron I, Markov P, Micevska A, Halaska M, Steffensen KD, Gristenko L, Nissi R, Lambaudie E, Tsitsishvili Z, Haidopoulos D, Dimitrios T, Novak Z, Peiretti M, Dunanova G, Macuks R, Hetland TE, Michelsen TM, Martins FC, Achimas-Cadariu P, Ulrikh EA, Uharcek P, Malic S, Ognjenovic D, Zapardiel I, Johann S, Sukhin VS, Manchanda R.
40.	Cervix leiomyosarcoma: clinical case.	Oncology. – 2011; 2(48): 166-8.	3	V. Sukhin, A.A. Mihanovsky, E.N. Sukhina, T.P. Grischenko, O.V. Splihina, A.I. Granovskaya, A.A. Radchenko
41.	Accompanying therapy with melatonin at radiation therapy for endometrial cancer.	Ukrainian Journal of Radiology - 2011;2(19): 201-3.	3	N. Prohach, P. Sorochan, I. Gromakova, I. Krugovaja, V. Sukhin

42.	The method of combined treatment of operable cervical cancer.	Patent №61210 UA, MPK A61N 5/10 (2006.01). registered on 11.07.11	3	Sukhina O. N., Svinarenko A.V., Sukhin V.S., Granovskaja A.I.
43.	Clinical peculiarities of the uterine cervix leiomyosarcoma.	Int J Gynecol Cancer -2011;21: suppl.3. -p.1260 http://dx.doi.org/10.1097/IGC.0b013e318235bd21	1	V. Sukhin, A. Mihanovskiy, E. Sukhina, A. Granovskaja, O. Slobodjanjuk
44.	Peculiarities of cryo-radiation tumor pathomorphosis in endometrial cancer.	J Clin. Oncol. -2011. -Spec. edition II: Abstr. Book of XII congress of oncologists of Ukraine. - p.203.	1	A. Mihanovskij, O. Lukashova, O. Slobodjanjuk, I. Krugova, N. Schit, V. Sukhin, N. Fedorenko
45.	Efficacy of chronoradio-chemotherapy in cervical cancer patients.	J Clin. Oncol. -2011. -Spec. edition II: Abstr. book of XII congress of oncologists of Ukraine. p.209-10.	2	O.N. Sukhina, A.V. Svinarenko, V.P. Starenkij, V. Sukhin, A.I. Granovskaja
46.	Assessment of efficacy of combination treatment of patients with ovarian cancer using neoadjuvant therapy.	Ukrainian Journal of Radiol. - 2011;3(19): - p. 368.	1	O. Slobodjanjuk, N. Schit, V. Sukhin, N. Fedorenko
47.	The peculiarities of uterine sarcoma relapses.	Ukrainian Journal of Radiol. - 2011;3(19): - p. 369.	1	V. Sukhin, N. Fedorenko, O. Slobodjanjuk, N. Schit
48.	The results of treatment and analysis of the level of tumor marker SCCA in patients with stage IIA cervical cancer.	Ukrainian Journal of Radiol. - 2011;3(19): - p. 369-70.	2	M. Teplova, Ju.V. Kharchenko, V. Sukhin, O. Slobodjanjuk
49.	A giant uterine fibromioma in nulliparous woman. Case report.	Journ «Health of woman» - 2011. -№2 (58). - p. 97-100.	4	V. Sukhin, A. Mihanovskij, I. Krugovaja, O. Slobodjanjuk, L. Skripnik1 N. Fedorenko, A. Radchenko
50.	Clinical features of uterine sarcoma.	Oncol and Radiol in Kazahstan. - 2011. - №4 (21). -p.46.	1	Sukhin V., Mihanovskij A., Sukhina E., Krugovaja I., Slobodjanjuk O., Fedorenko N., Granovskaja A.
51.	Training in Gynaecology Oncology Across Europe.	Textbook of gyn. oncology. Gunes Publ.- 2012. Section XIV. P.1103-15.	1	V. Sukhin
52.	The efficacy of chemo sensibilisator “Gidrea” in radiochemotherapy of patient with locally advanced cervical cancer.	Ukrainian Journ of Radiology - 2012;2(20): 207-11.	5	Sukhina E., Svinarenko A., Sukhin V., Prohach N., Starenkij V., Granovskaja A.

53.	Accompany therapy by Lycopid and Melatonin in treatment of endometrial cancer patients.	Ukrainian Journ of Radiol. - 2012; 2(20): 180-3.	4	N. Prohach, P. Sorochan, I. Gromakova, V. Sukhin, O. Kuzmenko
54.	Evaluation of neoadjuvant chemotherapy efficacy, depending on histological structure in ovarian cancer patient with advanced stage.	Abstract book of Ukrainian conference of young scientists. – Kharkov, 2012. – p.137-8.	2	O. Slobodjanjuk, N. Schit, V. Sukhin, Ju. Kharchenko
55.	Peculiarities of vulvar cancer relapse, depending on localization and tumor grade.	Abstract book of Ukrainian conference of young scientists. – Kharkov, 2012. – p.143-4.	2	V. Sukhin, O. Slobodjanjuk
56.	Distant results of conservative treatment of locally advanced cervical cancer patients with radiosensibilisation by Gidrea.	Scientific works (Journ.). Series: «Technogenic safety». – 2012. – ed.175; Vol.187. –p. 94–9.	6	Sukhina E.N., Svinarenko A.V., Sukhin V., Tarasova O.N., Granovskaja A.I.
57.	Distant results of Gidrea radiosensibilisation in conservative treatment of locally advanced cervical cancer patients.	Int meeting «Olvijsky forum - 2012: Ukrainian strategy in geopolitical space». Abstr.book. Sevastopol, Krim, Ukraine. – p.58.	1	Sukhina E.N., Svinarenko A.V., Sukhin V., Tarasova O.N., Granovskaja A.I.
58.	Nuclear medicine – modern situation and world development tendencies: methodical recommendations in course of medical radiology.	Methodics recommendations Kharkov: Karasin National University, 2012. – 52 pp.	52	Svinarenko A.V. Amirasjan S.A. Sukhin V.
59.	Radiation therapy: methodical recommendations in course of medical radiology.	Methodics recommendations Kharkov: Karasin National University, 2012. – 60 pp.	60	Svinarenko A.V. Amirasjan S.A. Sukhin V.
60.	Clinical peculiarities of vulvar cancer patients.	Journ «Health of woman» - 2012. -№6 (72). -p.192-4.	3	V. Sukhin
61.	Role of radiation therapy in treatment of primary ovarian cancer.	14th meeting of Int Gyn Cancer Society. Vancouver, Canada. 10.2012. Abstr. book, p. 410.	1	V. Sukhin, L. Sabobonina, E. Sukhina, A. Granovskaja
62.	Efficacy of treatment of vulvar cancer patient stage IA – IVA.	Abstr.book VII meeting of Oncol and Radiol of UIS, In Kazahstan, IX.2012. – p. 381.	1	V. Sukhin, O.V. Slobodjanjuk, E.N. Sukhina, A.V. Svinarenko
63.	Long-term results of treatment of vulvar cancer patients.	Ukrainian Journ of Radiol. - 2012; 4(20). - p.405-10.	6	V. Sukhin
64.	Feasibility of using marker SCCA in locally advanced cervical cancer.	Neoplasm. – 2013: 1(11). –p.48-52.	5	V. Sukhin
65.	Treatment efficacy of vulvar cancer patients.	Experimental and clinical medicine. – 2012: 4(57). –p.128-31.	4	V. Sukhin

66.	The role of cytokines in development of hematological and immune disorders at radiation therapy for uterine body cancer.	Ukrainian Journ of Radiology. - 2013; 2(21). - p.232-4.	3	P. Sorochan, N. Prohach, I. Gromakova, I. Krugovaja, V. Sukhin
67.	Efficacy of treatment for stage I-II uterus leiomyosarcoma.	Ukrainian Journ of Radiology. - 2013; 2(21). - p.236-9.	4	V. Sukhin, O. Sukhina, V. Starenkij
68.	Ultrasound semiotic of ovarian cancer during neoadjuvant chemotherapy.	Abstr book of conference «Role of young scientists in the development of med. science and practice». —Kharkov, 2013. — p.169-170.	2	O.Slobodjanjuk, N. Schit, V. Sukhin
69.	The level of tumor marker CA-125, depending on stage of disease, in patient with advanced ovarian cancer during neoadjuvant chemotherapy.	Abstract book of conference «Role of young scientists in the development of med.science and practice». —Kharkov, 2013. — p.170-171.	2	O.Slobodjanjuk, V. Sukhin
70.	The frequency of detection of human papilloma virus in patients with cervical dysplasia.	Abstract book of conference «Role of young scientists in the development of med.science and practice». —Kharkov, 2013. — p.173-174.	2	V. Sukhin
71.	Possibilities of ultrasonography in the diagnosis of uterine sarcoma.	Journ «Health of woman». - 2013. -№6 (82). - p. 161-164.	4	R. Abdulaev, V. Sukhin, N. Semikoz, O. Sukhina, S. Pozdnjakov
72.	Enzymatic and genetic features of endometrial cancer of different tumor grade in patients of different age groups.	Journ «Health of woman». - 2013. -№6 (82) -p. 169-172.	4	S. Kartashov, R. Musaev, V. Sukhin
73.	Helical computed tomography and magnetic resonance imaging in diagnosis of uterine sarcomas.	Journ «Health of woman». - 2013. -№6 (82) -p.173-9.	7	L. Levitskaja, V. Sukhin,
74.	Palliative care in uterine sarcoma patients.	Journ «Health of woman». - 2013. -№6 (82). -p.180-1.	2	O. Slobodjanjuk, V. Sukhin, N. Schit
75.	Clinical features of uterine sarcoma.	Journ «Health of woman». - 2013. -№6 (82). - p. 182-5.	4	V. Sukhin
76.	Comparative characteristics of different treatment methods of brain metastasis.	Int. meeting «Olvijsky forum - 2013: strategy of countries of Black sea region in geopolitical space». Jalta, Krim, Ukraine. Abstr. book –2013. - p.55-7.	3	A.Svinarenko, O. Sukhina, V. Starenkij, T. Grischenko, A.Nasonova, V. Sukhin

77.	Multimodal attitude to rectal cancer treatment.	Int meeting «Olvijsky forum - 2012: Ukrainian strategy in geopolitical space». Sevastopol, Krim, Ukraine. Abstr.book – p. 58-60.	3	A.Svinarenko, O. Sukhina, V. Starenkij, T. Grischenko, A.Nasonova, V. Sukhin
78.	The need for more workshops in laparoscopic surgery and surgical anatomy for European gynaecological oncology trainees: a survey by the European Network of Young Gynaecological Oncologists.	Int J Gynecol Cancer - 2013;23(6):1127-32. doi:10.1097/IGC.0b013e31829703b0 http://www.ncbi.nlm.nih.gov/pubmed/23792606	6	R. Manchanda, M.J. Halaska, J.M. Piek, J.P. Grabowski, D. Haidopoulos, I. Zapardiel, M. Gultekin, B. Vranes, K. Dallaku, M. Bossart, and European Network of Young Gynecological Oncologists (ENYGO): ..., V.S. Sukhin ,...
79.	Peculiarities of relapse in vulvar cancer patients, depending on tumor grade and localization.	Int Journ Gyn Cancer –2013, - Vol.23, Iss.8, Suppl.1. –p.1212. Abstr. book. 18th Int meeting of the Eur. society of Gyn Oncol. http://dx.doi.org/10.1097/01.IGC.0000437414.49882.6a	1	V. Sukhin, O. Slobodjanjuk, A. Granovskaja, E. Sukhina, A. Svinarenko
80.	Individual analysis of the tumor marker CA-125 in the course of neoadjuvant chemotherapy in patients with advanced ovarian cancer	Ukrainian Journ of Radiology. - 2013; 3(21). - p.289-94.	6	E. Sukhina, O. Slobodjanjuk, V. Sukhin, O. Tarasova, L. Skrypnik, L. Lanko
81.	The results of the multimodality treatment of uterine leiomyosarcoma	Ukrainian Journ of Radiology. - 2013; 3(21). - p.295-300.	6	E. Sukhina, V. Sukhin, O. Slobodjanjuk
82.	Method of polychemotherapy in ovarian cancer.	Patent №87903 UA, MPK A61K 33/24 (2006.01). registered 25.02.14 (iss. №4)		O. Sukhina, O. Mihanovsky, O. Slobodjanjuk, V. Sukhin
83.	Evaluation of efficacy of Pregabalin («Lyrica») in case of peripheral neuropathy in ovarian cancer patients during chemotherapy.	Abstract book of conference «Role of young scientists in the development of med. science and practice». —Kharkov, 2014. — p.186-7.	2	V. Sukhin, O. Satz, O. Spljuhina, O. Slobodjanjuk, V. Zub, A. Granovskaja
84.	Outcome of combined treatment of patients with endometrial stromal sarcoma.	Abstract book of conference with international participation «Role of young scientists in the development of med. science and practice». —Kharkov, 2014. — p.187-8.	2	V. Sukhin, O. Slobodjanjuk, K. Nermalzova, A. Granovskaja, A. Nesterenko
85.	Surgical treatment of uterine sarcoma patients. Review.	Journ «Health of woman». – 2014: 5 (91); p.46-9.	4	V. Sukhin
86.	Results of combined treatment of patients with endometrial stromal sarcoma.	Int Journ Gyn Cancer -Nov.2014, Vol. 24, Suppl. 4, p. -1535. http://dx.doi.org/10.1097/01.IGC.0000457075.08973.89 15th meeting of Int Gyn Cancer Society.	1	V. Sukhin, O.V. Slobodjanjuk, O.M. Sukhina, L.D. Skripnik, Y.N. Shen, V.A. Zub

87.	The results of comprehensive treatment of early-stage uterine leiomyosarcoma	Scientific works Journ. Series: «Technogenic safety». -2014. -Ed. 226(238). –p.67-72.	6	O. Sukhina, V. Sukhin, V. Starenkiy, A. Svinarenko, T. Grischenko, A. Nasonova, I. Belozorov
88.	Dynamics of tumor marker CA-125 in the course of neoadjuvant chemotherapy in patients with advanced ovarian cancer	Problems of continuous med education and science. – 2014:1: 21-4.		O.M. Sukhina, O.V. Slobodjanjuk, V. S. Sukhin
89.	Preoperative irradiation in treatment of the vulvar cancer patients.	Rad diagn., rad therapy. – 2014: 1-2: 136-7. Abstracts, Meeting of Assoc Radiol of Ukraine	1	V.S. Sukhin
90.	Analisis of combined treatment results of uterine leiomyosarcoma stage I-II.	Rad diagn., rad therapy. – 2014: 1-2: 137. Abstracts, Meeting of Assoc Radiol of Ukraine	2	O.M. Sukhina, V. S. Sukhin, G.I. Hranovskaya
91.	Preservation of reproductive function in cervical cancer patients, using assisted reproductive technologies.	Abstract book of conference «Role of young scientists in the development of med. science and practice: New perspectives» — Kharkov, 2015. – p.80-1.	2	V. Sukhin, V.A. Feskov, E.V. Blazhko, E.V. Somova
92.	Investigation of molecular-biological features of uterine sarcoma.	Abstract book of conference with international participation «Role of young scientists in the development of med. science and practice: New perspectives» — Kharkov, 2015. – P.105.	1	V. S. Sukhin, O.V. Slobodjanjuk, A. I. Granovskaya
93.	Evaluation of possible application of tumor marker HE4 in ovarian cancer diagnostic.	Abstract book of conference «Role of young scientists in the development of med. science and practice: New perspectives» — Kharkov, 2015. – p.106-7.	2	V. Sukhin, E.Nemaltsova, Yu. Kharchenko, N. Schit
94.	Tumor radiosensibilisation in treatment of persistant and recurrent ovarian cancer.	Abstract book of VI meeting of Ukr. society of radiobiologists. – X.2015. - Kyiv - P.122.	1	O. Sukhina, A. Svinarenko, V. Sukhin, A. Granovskaja
95.	Investigation of molecular-biological features of uterine sarcoma.	Int Journ Gyn Cancer –2015, - Vol.25, Iss.9, Suppl.2. – p.1153. http://dx.doi.org/10.1097/01.IGC.0000473498.85773.6e Abstr. book. 19th Int meeting of the Eur. society of Gyn Oncol.	1	V. Sukhin, O. Slobodyanyuk, O. Sukhina, O. Dolgaya
96.	Survival analisis of endometrial stromal sarcoma.	Eurasian Oncol Journ. –2015. - № 3(6). Suppl., – p.71. Abstr. book conference, Chernigov	1	V. Sukhin, O. Sukhina, A. Mihanovskiy, O. Slobodjanjuk, L. Skripnyk, A. Nasonova. A.Svinarenko
97.	Analysis of specificity of tumor-associated marker HE-4 for ovarian cancer diagnostic.	Eurasian Oncol Journ. –2015. – № 3(6). Suppl., – p.79. Abstr. book conference,	1	O. Sukhina, E. Nermalzova, V. Sukhin, A. Mihanovskiy,

		Chernigov		Ju. Shen, V. Zub
98.	Lymphopenia prevention in uterine cancer patients during radiation therapy.	№376-2015, Iss. 3 «Med. radiology», p. №4 - 24.09.2015. Ministry of education and science, Ukraine. Ukr.med.patentinfo. Infoletter about Implementation.	4	N. Prohach, P. Sorochan, I. Gromakova, I. Krugovaja, V. Sukhin
99.	Retrospective analysis of complex treatment results in endometrial stromal sarcoma patients.	Journ. «Problems of continuous med. education & science». – 2015: 4(20); p.55-9.	5	V. Sukhin, O. Sukhina
100.	Insulin resistance and endometrial cancer	Experiment and clinic med. - 2015: 4(69): 10-20.	11	I.A. Gromakova, P.P. Sorochan, N.E. Prokhach, V.S. Sukhin, T.S. Bakay, I.S. Gromakova
101.	Evaluation of possibility of tumor marker HE-4 application for ovarian cancer diagnostic.	Ukrain. Journ. Radiol. -2016: 1(24): 4-7.	4	O. Sukhina, O. Mihanovskiy V. Sukhin, E. Nemaltsova, Yu. Kharchenko
102.	Evaluation method of tiredness grade in endometrial cancer patients.	Patent №104857 UA, MPK G01N 33/48 (2006.01), registered on 25.02.16 (iss. №4).	4	N. Prohach, P. Sorochan, I. Gromakova, V. Sukhin, O. Gromakova
103.	Sensitivity detection of tumor marker HE-4 in patients with ovarian masses.	Abstr. book of Int. conference «Med. Science and clin. practice» – Kharkov. -2016. –p.92.	1	V. Sukhin, E. Nemaltsova, N. Fedorenko
104.	Application of diagnostic laparoscopy in ovarian cancer patient with advanced disease.	Ukrain. Journ. of Radiol. –2016. – Spec. edition. - Iss. 1 (228 p.). - p.134-5. Abstr. Book of XIII congress of Oncologist and radiologist of Ukraine, Kiev.	2	V. Sukhin, O. Mihanovskiy, I. Krugovaja, Ju. Kharchenko, N. Schit, M. Teplova, N. Fedorenko
105.	Relapse-rate in leiomyosarcoma patients stage I–II, depending on treatments program.	Ukrain. Journ. of Radiology – 2016. – Spec. edition. -Iss. 1 (228 p.). -p.135. Abstr. Book of XIII congress of Oncologist and radiologist of Ukraine, Kiev.	1	V. Sukhin, O. Sukhina, O. Mihanovskiy, O. Slobodjanjuk, L. Skrypnyk., A. Nasonova, A. Svinarenko
106.	Investigation of the possibility of application of tumor marker HE-4 for ovarian cancer diagnostic.	Ukrain. Journ. of Radiology – 2016. – Spec. edition. -Iss. 1 (228 p.). -p.136. Abstr. Book of XIII congress of Oncologist and radiologist of Ukraine, Kiev.	1	O. Sukhina, V. Sukhin, E. Nemaltsova
107.	Detection of the informative value of the tumor marker HE-4 in patients for ovarian tumors.	Abstr. Book II Forum «White nights», St.Petersburg. –2016. - p.215.	1	V. Sukhin, E. Nemaltsova, O. Sukhina

108.	Method of evaluation of tiredness syndrome in uterine cancer patients after treatment	Belarus. Oncol. Journ. – 2016. - Vol.8, Iss.3 (38). –p.32-37	5	N. Prohach, V. Sukhin, P. Sorochan, I. Gromakova
109.	Evaluation of the diagnostic value of tumor marker HE-4, depending on morphological structure of ovarian tumor.	Journ «Actual problem of modern medicine». – 2016. – Vol. 16, Iss. 3 (55), –p. 171–175.	5	E.Nemaltsova, O.Sukhina, V. Sukhin
110.	Advisability of adjuvant hormone-therapy in leiomyosarcoma patients stage I-II.	Int J Gyn Cancer –2016, - 2(26), Suppl.2. –p.81. Abstr. book. ESGO meeting. Prevention in Gyn malign. http://dx.doi.org/10.1097/01.IGC.0000502816.53587.26	1	V. Sukhin, O. Sukhina, L. Skrypnyk, O. Slobodjanjuk, A. Nasonova
111.	A call for new communication channels for European gynaecological oncology trainees - a survey on educational needs and social media use by the European Network of Young Gynaecological Oncologists.	Int J Gyn Cancer –2016. - Vol. 26, Suppl. 3. -p.598-9. 16th meeting of Int Gyn Cancer Society. http://dx.doi.org/10.1097/01.IGC.0000503327.50238.5c	2	K. Zalewski, K. Lindemann, M. Halaska, I. Zapardiel, R. Laky, E. Chereau, D. Lindquist, S. Polterauer, V. Sukhin, P. Dursun
112.	Method of prognosis for relapsed disease in uterine leiomyosarcoma patients.	Patent №111936 UA, MPK G01N 33/48 (2006.01), registered on 25.11.16 (iss. №22).	3	O. Sukhina, V. Sukhin A.Nasonova, I. Yakovtsova, O. Dolgaja
113.	Recommendation concerning hormone-therapy in leiomyosarcoma patients.	Actual problem of modern medicine. –2016. –Vol. 16. Iss. 4 (56) . –p.346–350.	5	V. Sukhin
114.	Multiple metastatic diseases of female genitalia, arising from primary gastric cancer.	Ukrain. Journ. Radiol. -2016. – Vol. XXIV, Iss.4. –p.59–64.	6	N. Krasnosleskiy V. Sukhin, S. Balaka, O. Sukhina, A. Panov, A. Datchenko, I. Ponomarev
115.	Method of prognosis for lymphopenia development in endometrial cancer patients.	Patent №113479 UA, MPK G01N 33/50 (2006.01), registered on 25.01.17 (iss. №4).	4	P. Sorochan., N. Prohach., I. Gromakova, V. Sukhin, O. Kuzmenko
116.	A Call for New Communication Channels for Gynecological Oncology Trainees: A Survey on Social Media Use and Educational Needs by the European Network of Young Gynecological Oncologists	Int J Gyn Cancer. –2017. - Vol. 27. N.3. -p. 620-6. doi: 10.1097/IGC.0000000000000917	7	K. Zalewski, K. Lindemann, M. J. Halaska, I. Zapardiel, R. Laky, E. Chereau, D. Lindquist, S. Polterauer, V. Sukhin, P. Dursun
117.	The technique of ovarian preservation in cervical cancer patients at combined treatment.	Abstr.book XIV Int. meeting students, scientists and doctors. – Kharkiv: Karazin Nat.Uni, -2017. – Vol.2. –p.63-4.	2	O. Sukhina, A. Svinarenko, V. Sukhin, A. Symbyreva

118.	The efficacy of hormonotherapy in hormonpositive uterine leiomyosarcoma.	Journ. «Problems of continuous med. education & science». – 2017. -1(24). –p. 39-43.	5	V. Sukhin, O. Sukhina, O. Mihanovskiy, A.Nasonova, Fan Livey
119.	The first experience of Fast-track surgery in oncogynecological clinic.	Ukrain. Journ. of Radiol. –2017. Suppl.1.– p.62–3. Abstr. «Modern tendency in intensive care in oncoradiology»	2	V. Sukhin, V. Seredenko, N. Fedorenko
120.	The evaluation of treatment efficacy of localised leiomyosarcoma.	Journ Kharkiv surg school. - 2017. -№ 3-4(84-85). -p.127-131.	5	V. Sukhin
121.	The choice of surgery in uterine sarcoma patients. Review and our experience.	Journ Kharkiv surg school -2017. -№.5-6 (86-87). -p.102-106.	5	V. Sukhin
122.	The influence of some clinical factors on patients' survival in endometrial stromal sarcoma.	Journ Science &Health. Kazakhstan. –2017. –№3. –p. 59-73.	15	V. Sukhin
123.	Radiation therapy in uterine sarcoma treatment.	Abstr. VII Int meeting of Ukr Rad Soc., Chernivtsy, Ukraine. -Jun 2017, -p. 40–41.	2	O.Sukhina, V.Sukhin E. Nemaltsova,
124.	The influence of some clinical factors on survival of endometrial stromal sarcoma patients.	Int Journ Gyn Cancer –2017. - Vol.27, Iss.9, Suppl.4. –p.467. Abstr. book. ESGO 20th. http://dx.doi.org/10.1097/01.IGC.0000527296.86225.87	1	V. Sukhin, O. Sukhina, V. Kolomatskaja, N. Fedorenko
125.	Surgical ovarian transposition. Section – Prevention strategies during Radio- and/or Chemotherapy.	Textbook of Cancer in Pregnancy. ESGO. -2017. -Section 3.2 – p.p. 155-161.	7	V. Kesic, M. Lambertini, L. Del Mastro, V. Sukhin
126.	Radiation therapy in uterine sarcoma patients stage I–II.	Ukrain. Journ. Radiol. -2017. - №4. Vol.XXV. -p.286-9.	4	V. Sukhin
127.	The morphological features of uterine sarcoma.	Journ. «Problems of continuous med. education & science». – 2017. – 4(27). –p.79-87.	9	V. Sukhin, O. Dolgaya.
128.	The significance of immunohistochemical markers for individualisation of the combined treatment of uterine sarcoma.	Inform letter. –№ 282. –2017. Iss.7. «Med. Radiology». Kiev, Ukraine.	2	O. Sukhina, I. Yakovtsova, O. Dolgaya, V. Sukhin, I. Krugovaya, A. Symbyreva
129.	The diagnostic significance of the tumor marker HE-4 in the staging of ovarian cancer.	Journ Science &health. –2017. - №6. –p.28-42.	15	O.Sukhina, V.Sukhin
130.	Prognostic value of lymph node ratio and number of positive inguinal nodes in patients with vulvar cancer.	Gynecol Oncol. -2017 Oct;147(1):92-97. doi:10.1016/j.ygyno.2017.07.142.	6	Polterauer S, Schwameis R, Grimm C, Macuks R, Iacoponi S, Zalewski K, Zapardiel I; VULCAN Study Collaborative Group:..., Sukhin V.,...et al.

131.	Optimization of the complex treatment of uterine sarcoma by determining the levels of tumor malignancy.	Methodic recommend. Kharkiv, -2017. – 17 p.	17	O. Sukhina, V. Sukhin, A.Nasonova
132.	The prognostic value of serum tumor-associated markers HE-4 in ovarian cancer patients.	Journ. «Problems of continuous med. Education & science». – 2018. –№ 1 (28). –p. 62–67	6	O. Sukhina, V.Sukhin, E. Nemaltsova
133.	Early radioepitheliitis of vagina in endometrial cancer patients.	Ukr. Radiol. Journ. -2018. - №1.T.XXVI. -p.38-41.	4	A, Simbyreva, O. Sukhina, V. Sukhin
134.	Possibilities of the diagnostic and prognostic application of matrix metalloproteinases in oncogynecology (Review and own results).	Actual problem of modern medicine. –2018. –Vol. 18. Iss. 1(61). –p. 313–7.	5	M.Krasnoselskiy, V.Sukhin, V. Hertman, L. Simonova- Pushkar
135.	The influence of radiation therapy on the treatment efficacy in leiomyosarcoma patients stage I-II.	Radiol. Visnik. –2018. –1-2(66-67). – p.100. Abstracts.	1	O.Sukhina, V. Sukhin, E. Nemaltsova, H. Granovska
136.	Results of the use of laparoscopy in ovarian cancer patients stage III-IV.	Ukrain. Journ. Radiol. –2018. Suppl.1.–p. 45. Conference abstr. book	1	O. Mihanovskiy V. Sukhin, Yu. Kharchenko, I. Krugovaya, N. Schit, M.Teplova, N. Fedorenko
137.	The experience of laparoscopic operations in patients in oncogynecological clinic.	Ukrain. Journ. Radiology. – 2018. Suppl.1.– p. 54-5. Conference abstr. book	2	V. Sukhin, N. Fedorenko, Yu. Moiseenko, Yu. Kharchenko, O. Mihanovskiy, L. Skrypnyk
138.	The investigation of differential diagnostic criteria for leiomyoma and uterine sarcoma based on techniques of three-dimensional echography.	Abstr. Book. “Perspective development directions in scienceand technic” –2018. –p. 46-9.	4	K.Yakovenko V. Sukhin
139.	Undifferentiated uterine sarcoma. Clinical and morphological features.	Belarus. Oncol Journ. –2018. - V. 12. Iss. 1 (45). –p. 5–11.	7	V. Sukhin, O. Sukhina, S.Danilyuk
140.	Expression of some molecular biological markers as a prognostic factor in uterine leiomyosarcoma.	Actual problem of modern medicine. –2018. –Vol. 18. Iss. 2 (62). –p.113–8.	6	V. Sukhin, O. Sukhina, I. Sokur, O. Sadnipyranij, V. Demchenko
141.	Non-typical mesenchymal uterine tumor, represented by cystadenoma. (A clinical case-report. Review).	Journ «Health of woman». 2018.2(128):16–18. doi 10.15574/hw.2018.128.16	3	V. Sukhin, O. Slobodyanyuk, L. Skrypnyk
142.	Features of the clinical course of undifferentiated uterine sarcomas.	Azerbaijan J Oncol. –2018. –№1. –p.31-4.	4	V. Sukhin

143.	Conservative management of endometrial cancer. A survey amongst European clinicians.	Arch Gynecol Obstet. -2018: 298(2): 373-380. doi: 10.1007/s00404-018-4820-7.	8	La Russa M, Zapardiel I, Halaska MJ, Zalewski K, Laky R, Dursun P , Lindquist D , Sukhin V., Polterauer S, Biliatis I.
144.	Individualized treatment of uterine sarcoma patients, taking into consideration the molecular-biological tumor features	Journ «Health of women». –2018. - №5(131). –p. 26-30.	5	V. Sukhin
145.	The analyse of treatment efficacy of leiomyosarcoma patients.	J Clin. Oncol. –2018. - №2(30). – p. 148-151.	4	V. Sukhin
146.	Expression of the p53 gene and matrix metalloproteinase-9 at different morphological types of uterine sarcoma.	Oncol and Radiol in Kazakhstan. – 2018. №2(48). –p.13-7	5	V. Sukhin
147.	Expression of MMP -9 as a prognostic factor for uterine sarcoma.	Reports of morphol. -2018. - №1 (24). p. 21-7. doi: 10.31393/morphology-journal-2018-24(1)-04	7	V. Sukhin, S. Danilyuk, O. Sukhina, O. Sadnipyranij, David Lindquist, Helena Hermelin, Miklós Tarján
148.	The role of the dose of adjuvant radiation therapy for uterine sarcoma stages I-II.	Ukrain. Journ. Radiol. – 2018. - №2. Vol.XXVI. –p.102-5.	4	V. Sukhin
149.	The content of matrix metalloproteinase-9 in patients with uterine mesenchymal tumors.	Journ. «Problems of continuous med. Education & science». – 2018. – № 2 (29). –p. 70–4	5	V.Sukhin, S.Danilyuk; V. Hertman
150.	Investigation of PDL-1 expression as a prognostic marker for uterine sarcoma.	Morphology. –2018. -№2. Vol.2. –p. 62-71. doi: 10.26641/1997-9665.2018.2.62-71	10	V. Sukhin, S. Danilyuk, O. Sukhina, O. Sadnipyranij, D. Lindquist, H.Hermelin, M. Tarján
151.	The investigation of PD-L1 expression as a prognostic marker for uterine sarcoma	Int J Gyn Cancer –2018, - Vol.28, Iss.2, Suppl.2. –p.568. IGCS meeting Kyoto. doi:10.1097/01.IGC.0000546279.09648.02.	1	V. Sukhin, S. Danyliuk, O. Sukhina, A. Zadnepryanniy, D. Lindquist, H. Hermelin, M. Tarján

152.	The importance of the study of the hemodynamics of the uterine tumors by the method of dopplerometry in the two- and three-dimensional echography modes for differential diagnostics of simple, proliferating leiomyomas and uterine sarcomas (review of literature)	«EUREKA: Health Sciences» - 2018. -№ 5. -p.40-6 doi: 10.21303/2504-5679.2018.00729	7	K. Yakovenko, V. Sukhin, T. Tamm, E. Yakovenko
153.	The method of Radiation therapy in uterine sarcoma stage I-II.	Patent №11733 UA, MPK A61N 5/10 (2006.01), publ. 10.07.18 (iss. №13).	6	O.Sukhina., V. Sukhin, A. Svyarenko
154.	Method of making prognose for ovarian cancer relapsed disease.	Patent №116752 UA, MPK G01N 33/48 (2006.01) Publ. on 25.04.2018 (iss. №8).	5	O. Sukhina, V. Sukhin, E. Nemaltsova
155.	The problems of evaluation of equality of high-tech medical equipment.	XI International conference, Institute of methrology. -2018. Abstr book. -p.73.	1	Korobchanskaya O.I., Vasil'eva E.N. V. Sukhin
156.	The possibility of the method 3D-energy dopplerography at differential diagnostic of isolated forms of adenomyosis and uterine leiomyoma associated adenomyosis.	Journ «Health of Woman». -2018. -№10(136). - p.136.	1	Yakovenko K.V., V. Sukhin
157.	3D-echography in diagnostic of genital endometriosis.	Journ. «Problems of continuous med. Education & science». – 2018. –№ 4 (32). p. 63–8.	6	Yakovenko K.V., Sukhin V., Tamm T.I., Yakovenko E.A.
158.	Intervention radiology in treatment of postoperative damages of urethrae.	Ukrain. Journ. Radiology. –2019. - №1. Vol.XXVII. –p.20-4.	5	S. Balaka, G. Grechikhin, N. Krasnoselskiy, O. Panov, V. Sukhin, M. Verbitskiy, O. Suhodolskaya, D. Veremiy
159.	Experience of diagnostic laparoscopy use in patients with advanced ovarian cancer.	Int Med Journ. –2019. -№1(97). – T. XXV. –p.61-4. http://www.imj.kh.ua/archive/2019/1/13	4	O.A. Mihanovskii, V.S. Sukhin, Yu.V. Kharchenko, N.V. Fedorenko, Yu.A. Moiseyenko, M.A. Teplova
160.	SATEN III—Splitting Adjuvant Treatment of stage III Endometrial cancers: an international, multicenter study	Int J Gyn Cancer. –2019. -Vol. 29 (8). -p. 1271-9. doi: 10.1136/ijgc-2019-000643.	9	Kahramanoglu I, Meydanli MM, Taranenka S, Ayhan A, Salman C, Sanci M, Demirkiran F, Ortac F, Haidopoulos D, Sukhin V , Kaidarova D, Stepanyan A, Farazaneh F, Aliyev S, Ulrich E, Mavrichev S, Akilli H, Sari ME, Pletnev A, Aslan K, Bese T, Kairbayev M, Vlachos D, Gultekin M

161.	Individualized approach to treatment of uterine sarcoma patients.	Ukrain. Journ. Radiol. –2019. - №2. Suppl.2 – p.29. Conference Abstracts «Actual and perspective directions in clinical oncology». Kharkov, 2019.	1	Sukhin V.S., Sukhina O.M., Mikhanovsky O.A., Moisenko Yu.A., Fedorenko N.V., Kharchenko Yu.V., Schit N.M., Teplova M.A., Krugova I.M., Nasonova A .N., Slobodyanyuk O.V., Artyukh S.V., Svinarenko A.V., Danilyuk S.V.
162.	Saten III - splitting adjuvant treatment into subgroups of stage III endometrioid endometrial cancers: an international, multicenter study	Int J Gyn Cancer –2019. -Vol. 29, (suppl. 4). A331-2. http://doi.org/10.1136/ijgc-2019-esgo.601	2	Kahramanoglu I, Meydanli MM, Taranenka S, Ayhan A, Salman C, Sanci M, Demirkiran F, Ortac F, Haidopoulos D, Sukhin V, Kaidarova D, Stepanyan A, Farazaneh F, Aliyev S, Ulrich E, Mavrichiev S, Akilli H, Sari ME, Pletnev A, Aslan K, Bese T, Kairbayev M, Vlachos D, Gultekin M
163.	Preoperative radiochemotherapy with HDR-brachytherapy in combined treatment of cervical cancer	Ukr. Journ. Radiol. –2019. -№2. Suppl.3. –p.26-7. Abstr book «Actual problems of brachytherapy development in Ukraine».	2	Sukhin V.S., Sukhina O.M., Granovska H.
164.	Individual dose overload on the rectal mucosa during the postoperative radiation therapy in uterine cancer patients, based on the in vivo dosimetry data.	Ukr. Metrolog. journ. -2019, -N.4, -p.50-57. http://doi.org/10.24027/2306-7039.4.2019.195957	8	O. Sukhina, O. Vasilyeva, V. Sukhin, A. Simbirova, H. Hranovska, S. Artiukh
165.	Method of the complex treatment of uterine sarcoma patients stage I-II.	Patent №120904 UA, MPK A61N 5/10 (2006.01) A61K 35/13 (2015.01), Publ. on 25.02.2020	8	N. Krasnoselskiy, O. Sukhina, V. Sukhin
166.	The use of in vivo dosimetry within the combined treatment of uterine body cancer.	Oncol and Radiol in Kazakhstan. – 2020. №1(55). –p.30-2. http://doi.org/10.52532/2663-4864-2020-1-55-30-32	4	O.M. Sukhina, V.S. Sukhin, Y.B. Radzishavska, A.S. Simbirova
167.	SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer	Int J Gynecol Cancer - 2020;30:1269-1277. http://doi.org/10.1136/ijgc-2020-001506	9	Chiva L, Zanagnolo V, Querleu D, Martin-Calvo N, Arévalo-Serrano J, Căpîlna ME, Fagotti A, Kucukmetin A, Mom C, Chakalova G, Aliyev S, Malzoni M, Narducci F, Arencibia O, Raspagliesi F, Toptas T, Cibula D, Kaidarova D, Meydanli MM, Tavares M, Golub D, Perrone AM, Poka R, Tsolakidis D, Vujić G, Jedryka MA, Zusterzeel PLM, Beltman JJ, Goffin F, Haidopoulos D, Haller H, Jach R, Yezhova I, Berlev I, Bernardino M, Bharathan R, Lanner M, Maenpaa MM, Sukhin V , Feron JG, Fruscio R, Kukk K, Ponce J, Minguez JA, Vázquez-Vicente D, Castellanos T,

				Chacon E, Alcazar JL
168.	Prognostic factors in patients with vulvar cancer: the VULCAN study.	Int J Gynecol Cancer -2020;30:1285-1291. http://doi.org/10.1136/ijgc-2019-000526	7	Zapardiel I, Iacoponi S, Coronado PJ, VULCAN Study co-investigators:...group:.. <i>Sukhin V., et al.</i>
169.	Assessment of palliative care training in gynaecological oncology: a survey amongst ENYGO members (European Network in Young Gynaec-Oncologists).	<i>BMJ Supportive & Palliative Care. Online</i> -2020; -Vol.10 (4):1–4. http://doi.org/10.1136/bmjspcare-2020-002233	4	La Russa M, Zapardiel I, Zalewski K, Laky R, Dursun P, Sukhin V, Lindquist D, Lindemann K
170.	Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists.	Int J Gynecol Cancer 2021;31(4):575-584 http://doi.org/10.1136/ijgc-2020-002176		M. Lanner, T. Nikolova, B. Gutic, N. Nikolova, A. Pletnev, I. Selcuk, D.-Efthymios Vlachos, Z. Razumova, N. Bizzari, Ch. Theofanakis, P. Lepka, I. Kahramanoglu, S. Han, S. Nasser, S. Molnar, D. Hudry, R. Montero-Macias, N. de Lange, R. Macuks, M. F. Hasanov, R. Karimbayli, I. Gagua, C. Andrade, C. Pardal, J. Dotlic, R. M. Alvarez, M. Hruda, F. Fruhauf, L. Ekdahl, S. L. Antonsen, <i>V. Sukhin</i> , A. G. Zahl Eriksson, E. Gliozheni, R. Delic, A. Satanova, N. Kovacevic, L. Gristsenko, S. Babloyan, K. Zalewski, R. Bharathan
171.	Rare radiation complications after treatment of cervical cancer.	Ukr Journ med., biol. and sport. – 2020. -Iss.5. -№6(28). -p.176-181. http://doi.org/10.26693/jmbs05.06.176	6	O. Sukhina, K. Nemaltsova, V. Sukhin.
172.	Modern approach to problems of diagnostic and treatment of uterine sarcoma.	Textbook. -2020. Kharkiv: published by «Tochka», -131p. ISBN 978-617-7856-18-3	131	M.V. Krasnoselskiy, O.M. Sukhina, V.S. Sukhin, A.M. Nasonova
173.	Risk of recurrence of malignant tumors of the ovaries and levels of tumor markers HE-4 and CA-125.	Ukr jour of radiol and oncol. - 2020;28(4): 364-373 http://doi.org/10.46879/ukroj.4.20.20.364-373	10	O. Sukhina, K. Nemaltsova, V. Sukhin

174.	Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.	Gyn. Oncol. -2021; 161(2):502-7. http://doi.org/10.1016/j.vgyno.2021.02.018	6	J-E. Kurtz, V. Gebiski, V. Sukhin, M. Carey, I. Kong, RM. Glasspool, JS. Berek, M. de P. Batista, M. Hall, J.-W. Kim, E. Yeoshoua, N. Fujiwara, B.-H. Nam, S. Polleis, J.-Y. Lee, A. Strojna, L. Farrelly, R. Schwameis, R. Fossati, A.-S. Darlington, C.-H. Lai, A.A. Wright, O. Rosenblat, P. Harter, P. Roxburgh, R.R. Chowdhury, T.-Ch. Chang, X.r Paoletti, M. Friedlander
175.	Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators.	Int J Gynecol Cancer -2021: 31:1212–1219. http://doi.org/10.1136/ijgc-2021-002587		F. Boria, L. Chiva, V. Zanag nolo, D. Querleu, N. Martin-Calvo, M. Emil Căpîlna, A. Fagotti, A. Kucukmetin, C. Mom, G. Ch akalova, Aliyev Sh., M. Mal zoni, F. Narducci, O. Arencib ia, F. Raspagliesi, T. Toptas, D. Cibula, D. Kaidarova, M. Mutlu Meydanli, M. Tavares, D. Golub, A. Myriam Perrone, R. Poka, D. Tsolakidis, G. Vujić, M. A Jedryka, P. L M Zusterzeel, J.Jan Beltman, F. Goffin, D. Haidopoulos, H . Haller, R. Jach, I. Yezhova, I. Berlev, M. Bernardino, R. Bharathan, M. Lanner, M. MMAenpaa, V. Sukhin, J-G. Feron, R. Fruscio, K. Kuk k, J. Ponce, M. Alonso-Espías, J. Angel Minguez, D. Vázquez-Vicente, N. Manzour, M. Jurado, T. Cast ellanos, E. Chacon, J.L. Alca zar
176.	Prognostic factors for recurrence and survival in uncommon variants of vulvar cancer.	Arch Gynecol Obstet. - 2021;303(3):759-766. http://doi.org/10.1007/s00404-020-05813-x	8	Zapardiel I, Gracia M, Díez J, Buda A, Noya MC, Iaco P, Vieira-Baptista P, Iacoponi S; VULCAN Study collaborative group:... <i>Sukhin V., et al.</i>
177.	Application of HDR-brachytherapy in treatment of patients with operable cervical cancer.	Abstr. book. XIV congress of oncol and radiol. Ukraine, NCI. - 10.2021. -p. 307-8.	2	H. Hranovska, O. Sukhina, K. Nemaltsova, V. Sukhin, A.S. Simbirova
178.	The deviation between planned and really obtained dose, depending on constitutional features of endometrial cancer patients.	Abstr. book. XIV congress of oncol and radiol. Ukraine, NCI. - 10.2021. -p. 318-9.	2	A.Nesterenko, O. Sukhina V. Sukhin, V. Staren'kiy, A.S. Simbirova

179.	The individualized treatment of uterine sarcoma patients.	Abstr. book. XIV congress of oncol and radiol. Ukraine, NCI. - 10.2021. -p. 229-231.	3	V. Sukhin, H. Hranovska, O. Sukhina, A. Mihanovskiy, Ju.Kharchenko, Ju. Moiseenko, N. Fedorenko, N. Schit, M. Teplova, I. Krugovaja, A. Nasonova, S. Artiukh, A. Svinarenko, S. Daniliyuk, O. Dolgaya
180.	Dynamic dose fractionation of HDR-brachytherapy at preoperative irradiation of cervical cancer patients	Int. Journ of Gyn. Cancer - 2021;31:A11-A12. Abstr. 22th ESGO meeting. http://doi.org/10.1136/ijgc-2021-ESGO.15	2	V. Sukhin, H. Hranovska, O. Sukhina, K. Nemaltsova
181.	Evaluation of hormonal function in women with cervical insufficiency and infertility in the history.	Wiad Lek. 2021;74(10 p.I):2412-2416. PMID: 34896996. http://doi.org/10.36740/WLek202110109	5	O.M. Perkhulyn, L.V. Pakhareenko, V.S. Sukhin, O.V. Saltovskiy, V.M. Kovalchuk, H.I. Hranovska, O.V. Kravchenko
182.	Deviation between the planned dose and the in vivo dosimetry results during postoperative irradiation in patients with uterine cancer depending on anthropometric data.	Probl rad med and radiobiol. - 2021;26:573-586. http://doi.org/10.33145/2304-8336-2021-26-573-586	14	O. Sukhina, A. Simbirova V. Sukhin,
183.	SUCCOR cone study: conization before radical hysterectomy.	Int J Gynecol Cancer. 2022;32:117–124. http://doi.org/10.1136/ijgc-2021-002544	8	Chacon E, Manzour N, Zanagnolo V, Querleu D, Núñez-Córdoba JM, Martín-Calvo N, Căpîlna ME, Fagotti A, Kucukmetin A, Mom C, Chakalova G, Shamistan A, Gil Moreno A, Malzoni M, Narducci F, Arencibia O, Raspagliesi F, Toptas T, Cíbula D, Kaidarova D, Meydanli MM, Tavares M, Golub D, Perrone AM, Poka R, Tsolakidis D, Vujić G, Jedryka MA, Zusterzeel PLM, Beltman JJ, Goffin F, Haidopoulos D, Haller H, Jach R, Yezhova I, Berlev I, Bernardino M, Bharathan R, Lanner M, Maenpaa MM, Sukhin V , Feron JG, Fruscio R, Kukk K, Ponce J, Minguez JA, Vázquez-Vicente D, Castellanos T, Boria F, Alcazar JL, Chiva L; SUCCOR study group;

184.	European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.	Ann Oncol. 2022; 33:3. 276-287. http://doi.org/10.1016/j.annonc.2021.11.013	12	Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza MR, Brasiuniene B, Madry R, Brenton JD, Aulsems MGEM, Büttner R, Lambrechts D; European experts' consensus group:..... Sukhin V., et al.
185.	Radiation toxicology. Toxicology of main radionuclides. Methodical recommendations	Method. recommendations. Kharkiv: V.N. Karasin Kharkiv National Uni, 2022. – 24 pp.	24	V.S. Sukhin, S.A. Amirazyanyan
186.	SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer	Ann Surg Oncol. -2022;29:4819–4829. http://doi.org/10.1245/s10434-022-11671-5	11	Manzour N, Chiva L, Chacón E, Martín-Calvo N, Boria F, Minguez JA, Alcazar JL; SUCCOR Study Group:.... Sukhin V., et al.
187.	SUCCOR quality: validation of ESGO quality indicators for surgical treatment of cervical cancer.	Int J Gynecol Cancer. - 2022;32:1236-1243. http://doi.org/10.1136/ijgc-2022-003790	8	F. Boria, A. Kucukmetin, C. Mom, G. Chakalova, Sh. Aliyev, M. Malzoni, F. Narducci, O. Arencibia, F. Raspagliesi, T. Toptas, D. Cibula, D. Kaidarova, M.M. Meydanli, M. Tavares, D. Golub, A.M. Perrone, R. Poka, P.L.M. Zusterzeel, I. Aluloski, F. Goffin, D. Haidopoulos, H. Haller, R. Jach, I. Yezhova, M. Bernardino, R. Bharathan, M.M. Maenpaa, V. Sukhin , J.-G. Feron, R. Fruscio, K. Kukk, J. Ponce, F. Demirkiran, G. Vorgias, N. Povolotskaya, P.J. Coronado Martín, T. Marina, I. Zapardiel, N. Bizzarri, M. Gorostidi, M. Gutierrez, N. Manzour, A. Berasaluce, On behalf of the SUCCOR study Group
188	The influence of different treatment plans of brachytherapy on the morphological structure of the tumor cells in cervical cancer.	Radiol. news – 2022. – N.1-2. Abstr. Of VI Ukr. Scientif. Conf. with Int participation «Actual. Problems of rad.oncol. in Ukraine», Lviv. – 21-22.09.2022. -p. 82-3.	2	V. Sukhin, O. Lukasheva, G. Granovska, O. Sukhina, , K. Nematsova, K. Semenenko, A. Simbyrova
189.	Morphological features of the therapeutic pathomorphosis of cervical cancer after preoperative HDR-brachytherapy.	Abstr., VI Ukrain. scientif. conf. «Theory and practice of modern morphol.», Dnipro. -2022. -p.144-5. https://sites.google.com/a/dsma.dp.ua/confmorphology/materiali-konferenciie/konferencia-2022-roku	2	V.S. Sukhin, G.I. Granovska, S.V. Danilyuk

190.	Use of 3D planning of HDR brachytherapy in patients with cervical cancer.	Ukr jour radiol oncol. - 2022;30(3):22–32. http://doi.org/10.46879/ukroj.3.2022.22-32	11	K.V. Nemaltsova; O.M. Sukhina; A.I. Hranovska; A.V. Svnarenko; A.A. Svnarenko; V.S. Sukhin
191.	Treatment strategy and clinical characteristics of patients with cervical cancer as prognostic parameters of survival.	Ukr jour radiol oncol. - 2022;30(3):65-78. http://doi.org/10.46879/ukroj.3.2022.65-78	14	Ye.B. Radzishvetska; O.M. Sukhina; L.Ya. Vasylyev; V.S. Sukhin; K.V. Nemaltsova; H.V. Kulinich; O.O. Solodovnikova
192.	Morphological features of the therapeutic pathomorphosis of cervical cancer after preoperative HDR-brachytherapy.	Morphologia. -2022;16(4):26-31. http://doi.org/10.26641/1997-9665.2022.4.26-31	6	V.S. Sukhin, G.I. Granovska, S.V. Danilyuk
193.	Our experience of the hormonal therapy in uterine sarcoma patients.	ESMO Open (abstr. Sarcoma meeting). -2023;8(1, Suppl.2):101092. http://doi.org/10.1016/j.esmoop.2023.101092	1	V. Kovalchuk, M. Krasnoselskiy, V. Sukhin, O. Mihanovskiy, O. Sukhina, H. Hranovska, A. Nasonova, K. Nemaltsova, S. Danilyuk, O. Dolgaya
194.	An infographic model of a database for conducting an analytical study of the long-term consequences of cervical cancer treatment.	Ukr jour radiol oncol. - 2023;31(1):83-92. https://doi.org/10.46879/ukroj.1.2023.83-92	10	Ye.B. Radzishvetska; O.M. Sukhina; L.Ya. Vasylyev; V.S. Sukhin; K.V. Nemaltsova; O.O. Solodovnikova
195.	Prognostic factors in patients with uterine sarcoma: the SARCUT Study	Int J Gynecol Cancer. 2023;33:897-904. https://doi.org/10.1136/ijgc-2022-004204 .	8	I. Zapardiel, M. Gracia, Ro. Macuks, R. Mancari, P.Achimas-Cadariu, G. Corrado, A. Bartusevicius, V. Sukhin , J. C. Muruzabal, P. J. Coronado, B. Gardella, J. M. Piek, N. Concin, C. Arab, D. Papatheodorou, S. Polterauer, S. Iacoponi, T. Nieto, M. C. Lopez-Sanclemente, H. Trukhan, M. M. Gil, I. Bakinovskaya, A. Dalamanava, M. Cucurull, D. Rovski, L. Baquedano, L. Chiva, M. Mardas, S.Mavrichev, J. Klat, C.A. Lopez de la Manzanara, Y. Yildirim; on behalf of <i>SARCUT Study Group</i> .
196.	Prognostic factors in undifferentiated uterine sarcoma: a subanalysis of the SARCUT study.	Arch Gyn & Obst. 2023. 308, 981–988. https://doi.org/10.1007/s00404-023-07057-x	8	R. Macuks, Y.Yildirim R. Mancari, P. Achimas-Cadariu, Th. K. Madhuri, E. Ortega, M. R. Mallmann, I. Zapardiel, SARCUT Study collaborative group: ...Sukhin V., et al.

197.	SUCCOR nodes: may sentinel node biopsy determine the need for adjuvant treatment?	Ann Surg Oncol. 2023; 30, 4975–4985. https://doi.org/10.1245/s10434-023-13529-w .	11	B.Gómez A, Martín-Calvo N, Boria F, Manzour N, Chacón E, Bizzarri N, Chiva L; SUCCOR Study Group:..., Sukhin V ,...et al.
198.	Influence of clinical and surgical factors on uterine carcinosarcoma survival.	Cancers. 2023, 15(5), 1463-1473. https://doi.org/10.3390/cancers15051463	11	M. Gracia, Yu. Yildirim, R. Macuks, R. Mancari, P. Achimas-Cadariu, S. Polterauer, S. Iacoponi, I. Zapardiel, on behalf of SARCUT Study Group:..., Sukhin V ,...et al.
199.	Lymph node dissection in uterine leiomyosarcomas: a matched-pair study.	Gynecol Oncol. 2023;3;174:28-33. https://doi.org/10.1016/j.ygyno.2023.04.007 .	6	Coronado PJ, Alonso-Espias M, Yildirim Y, Macuks R, Mancari R, Achimas-Cadariu P, Aniorte SM, Mitidieri M, Lambaudie E, Dubois N, Zapardiel I; SARCUT Study Group:..., Sukhin V ,...et al.
200.	Dostarlimab for primary advanced or recurrent endometrial cancer.	N Engl J Med. 2023; 8;388(23):2145-2158. https://doi.org/10.1056/NEJMoa216334	14	Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanka LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators: ... Sukhin V ,...et al.
201.	Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.	ASCO meeting, Abstr.book 2023;357s. Journ. Clin. Oncol. 2023; 41:16_suppl.: 5504. http://doi.org/10.1200/JCO.2023.41.16_suppl.5504	1	M.R. Mirza, M. A. Powell, C. Lundgren, V. Sukhin, Bh. Pothuri, L. Gilbert, S. Gill, G. Ronzino, N. Nevadunsky, S. Kommoss, L. Willmott, I. Boere, C. A. Mathews, J. Buscema, M. Teneriello, M. S. Shahin, O. Meyers, J. Garside, R. L. Coleman, B. M. Slomovitz
202.	The evaluation of the efficacy of different doses of the preoperative HDR-brachytherapy in treatment of cervical cancer stage IB-IIA, based on the electron microscopy investigation data.	Radiol. visnik – 2023. – N.1-2. Abstr.book, Ukr. scientif. conf. USTRO with Int particip. «Act. Probl. of rad. oncol. in Ukraine», Uzhgorod. – 22-23.08.2023. -p. 99.	1	Sukhina O., Lukashova O., Sukhin V., Hranovska H., Semenenko K.
203.	3D-planning of the HDR-brachytherapy in cervical cancer treatment.	Radiol. visnik – 2023. – N.1-2. Abstr.book, Ukr. scientif. conf. USTRO with Int particip. «Act. Probl. of rad. oncol. in Ukraine», Uzhgorod. – 22-23.08.2023. -p. 103-4.	2	Sukhina O., Nemaltsova K., Sukhin V., Hranovska H., Shustov I.

204.	Risk factors of local recurrence and distant metastasis and manifestations of toxicity during chemoradiation treatment of cervical cancer patients.	Ukr jour radiol oncol. - 2023;31(2):175–189. https://doi.org/10.46879/ukroj.2.2023.175-189	15	Radzishevskaya Yev. B, Sukhina OM, Vasylyev LYa, Sukhin VS, Nemaltsova KV, Radzishevskaya YaB, Boiko OM.
205.	Impact of Hospital Case Volume on Uterine Sarcoma Prognosis: SARCUT Study Subanalysis.	Ann Surg Oncol 2023 Nov;30(12):7645-7652. http://doi.org/10.1245/s10434-023-13826-4 PMID: 37460742	8	Gorostidi M, Yildirim Y, Macuks R, Mancari R, Achimas-Cadariu P, Ibañez E, Corrado G, Bartusevicius A, Sukhina O, Zapardiel I; SARCUT Study Group:.... Sukhin V ,...et al.
206.	Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)	Int J Gynecol Cancer. 2023, 33 (Suppl 3) A11-A12; (№540). http://doi.org/10.1136/ijgc-2023-ESGO.16	2	A. Auranen, D. Black, V. Sukhin , S. Sharma, G. Ronzino, L. M. Landrum, D. Bauerschlag, L. Willmott, R. Lalisang, J. Buscema, L. Gilbert, R.L. Coleman, D. Bender, A. Armstrong, N. Nevadunsky, M.A. Powell, C. Dabrowski, S. Stevens, M.R. Mirza, E. Fleming
207.	Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.	N Engl J Med. 2023 Dec 7;389(23):2162-2174. http://doi.org/10.1056/NEJMoa2309169 PMID: 38055253.	13	Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups:.... Sukhin V ,...et al.
208.	Impact of perioperative characteristics on the recurrence risk and survival of patients with uterine leiomyosarcoma.	Int J Gyn Obstet. 2023 Dec;163(3):868-874. http://doi.org/10.1002/ijgo.14998 PMID: 37485666.	7	Gracia M, Yildirim Y, Macuks R, Mancari R, Achimas-Cadariu P, Cusine-Lopez L, Novak Z, Dallaku K, Zapardiel I; SARCUT Study Group:.... Sukhin V ,...et al.
209.	Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial. NCT03981796	2023 ASCO Quality Care Symposium (ASCO QCS) 27-28 Oct. in Boston, JCO Oncol Pract 19, 2023 (suppl. 11; abstr 332). Doi: 10.1200/OP.2023.19.11_suppl.332	1	M. R. Mirza, Mark S. Shahin, M. A. Powell, C. Lundgren, V. Sukhin , B. Pothuri, L. Gilbert, S. Gill, G. Ronzino, N. S. Nevadunsky, S. Kommoss, L. Willmott, I. Boere, C. A. Mathews, J. Buscema, M. Teneriello, O. Meyers, J. Garside, R. L. Coleman, B. M. Slomovitz

210.	Patient-reported outcomes in primary advanced or recurrent EC for patients treated with dostarlimab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel in the RUBY trial.	14th Ann. AONN (Acad of Oncol Nurse & Pat Navigator) Conf., 15-19 Nov., San Antonio. Abstr. J Oncol Navigat Surv. – 2023, Nov., Vol.14, N.11, A12. https://www.jons-online.com/issues/2023/november-2023-vol-14-no-11/4983-category-ix-clinical-research#A12	1	M.R. Mirza, M. A. Powell, C. Lundgren, V. Sukhin , Bh. Pothuri, L. Gilbert, S. E. Gill, G. Ronzino, N. Nevadunsky, S. Kommoss, L. Willmott, I. Boere, C. Mathews, J. Buscema, M. G. Teneriello, M. S. Shahin, O. Meyers, J. Garside, R. L. Coleman, B. Slomovitz
211.	Therapeutic pathomorphosis of the cells of cervical cancer stage IB–IIA as an evidence of the effectiveness of preoperative HDR-brachytherapy.	Ukr jour radiol oncol. 2023;31(4):285–302. https://doi.org/10.46879/ukroj.4.2023.285-302	8	Sukhin V.S., Granovska, G.I., Sukhina O.M., Lukashova O.P., Teslenko I.M.
212	Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer.	Int J Gyn Cancer. 2024; 34: A42. 25th ESGO meeting, Barcelona, Spain. 7-10.3.2024. Abstract #285 https://doi.org/10.1136/ijgc-2024-ESGO.53	1	S. Pignata, V. Sukhin , N. Colombo, J. Korach, T. Matsumoto, S. Lalondrelle, Ju. Vizkeleti, L. Randall, V. Samouelian, P. Salman, A. Nogueira-Rodrigues, A. Ayhan, J. F. Cueva, Yo. M. Kim, E. Petru, K. Yamada, K. Li, E. Szamreta, Al. M. Nguyen, D. Lorusso
213.	Retrospective analysis of the clinical outcome of uterine cervix cancer patients with operable disease.	Int J Gyn Cancer. 2024; 34: A103. 25th ESGO meeting, Barcelona, Spain. 7-10.3.2024. Abstract #655 https://doi.org/10.1136/ijgc-2024-ESGO.184	1	V. Sukhin , O. Mikhanovskiy, O. Sukhina, H. Hranovska, V. Kovaltchuk, Yu. Shen, G. Shen, D. Sumtsov, H. Lohvyniuk, O. Onikienko, T. Volkov, I. Sokur, N. Mohyla, V. Maksymovskiy
214	Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.	Lancet. 2024 Mar 20:S0140-6736(24)00317-9. Epub ahead of print. PMID: 38521086. https://doi.org/10.1016/S0140-6736(24)00317-9 PMID: 38521086 IF 98.4	10	Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V , Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A, Christiaens M, Polterauer S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators.
215	Risk factors for local and distant metastasis and survival characteristics of patients with locally advanced cervical cancer, revealed on the basis of analysis of historical data for the	Ukr jour radiol oncol. 2024;32(1): 44-55. https://doi.org/10.46879/ukroj.1.2024.44-55	11	Radzishevskaya Y., Sukhina O., Vasylyev L., Sukhin V. , Nemaltsova K., Hranovska H., Radzishevskaya Y., Boiko O.

	period 1998–2021.			
216	Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG 3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk, locally advanced cervical cancer.	Conf. SGO 03.2024, San Diego, USA. Abstr.book Gyn.Oncol. -2024;190;Suppl. 1;S9 http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1016/j.ygyno.2024.07.020	5	<u>L. Randall</u> , V. Sukhin , N. Colombo, J. Korach, T. Matsumoto, S. Lalondrelle, J. Vizkeleti, V. Samouelian, R. Salani, P. Salman, A. Nogueira-Rodrigues, A. Ayhan, S. Frentzas, J.F. Cueva, Y.M. Kim, E. Petru, D.P. Milla, J. Schouli, V.V. Saevets, K. Yamada, K. Li, E. Szamreta, A.M. Nguyen, S. Pignata, D. Lorusso
217	Expression of p53 gene and its prognostic significance in patients with uterine sarcoma.	Abstr.book Int Society Gyn Endocrin (ISGE) meeting «Gyn endocrine the 21 st world congress». 8-11.5.2024, Florence, Italy. Abstract #P302.	1	V. Sukhin , O. Mihanovskiy, M. Teplova, A. Nasonova, N. Schyt, I. Kruhova, Yu. Kharchenko, K. Nemaltsova, H. Hranovska, Yu. Moiseenko, N. Fedorenko, O. Sukhina, V. Kovalchuk, S. Danilyuk, O.Dolgaya
218	Peculiarities of disorders of the hormonal cycle regulation in women of reproductive age during the war in Ukraine.	Abstr.book Int Society Gyn Endocrin (ISGE) meeting «Gyn endocrine the 21 st world congress». 8-11.5.2024, Florence, Italy. Abstract #P19.	1	V. Kovalchuk, V. Sukhin , O. Saltovskiy, O. Kobakovska
219	Risk factors for relapse in locally advanced cervical cancer.	Abstr. book Ukr Society Ther Radiol Oncol., 21-22.8.2024 Rivne, Ukraine. Radiology News. 2024;1-2(84-85): 80-81.	2	Sukhina O., Sukhin V. , Vasylyev L., Nemaltsova K., Radzishavska Y., Kolpak K., Hranovska H.
220	Safety of Dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).	Therapeutic Advances in Med. Oncol. 2024;16: 1-17. https://doi.org/10.1177/17588359241277656 PMID: 39346117 IF 4,3	17	Auranen A, Powell MA, Sukhin V , Landrum LM, Ronzino G, Buscema J, Bauerschlag D, Lalisang R, Bender D, Gilbert L, Armstrong A, Safra T, Nevadunsky N, Sebastianelli A, Slomovitz B, Ring K, Coleman R, Podzielinski I, Stuckey A, Teneriello M, Gill S, Pothuri B, Willmott L, Sharma S, Dabrowski Ch, Grace A, Stevens Sh, Mirza MR, Fleming Ev

221	Determination of risk factors for the occurrence of recurrences, metastases, and somatic complications after treatment of locally advanced cervical cancer using modern information technologies.	Ukr Journ Radiol Oncol. 2024;32(4):478-90. https://doi.org/10.46879/ukroj.4.2024.478-490 IF 1,24	13	Radzishevskaya, Y., Sukhina O., Vasylyev, L., Sukhin, V., Nemaltsova, K., Hranovska, H., Solodovnikov, A.
222	Patient-reported outcomes with pembrolizumab plus chemoradiotherapy for high-risk, locally advanced cervical cancer: interim analysis 2 results from the randomised, double-blind, phase 3 engot-cx11/gog-3047/keynote-a18 study.	Int J Gyn Cancer. 2025;35;2(Suppl.1):101697 #691 26th ESGO meeting Rome, Italy, 19-22.2.2025 https://doi.org/10.1016/j.ijgc.2025.101697	2	V. Sukhin , S. Pignata, R. Lazzari, J. Korach, T. Matsumoto, S. Lalondrelle, B. Aktas, R. Salani, V. Castonguay, P. Rodriguez, F. Cruz, H. Akilli, L. Gonzalez Cortijo, Ya. Xiang, I. Tsibulak, K. Yamada, P. Liu, E. Szamreta, A. Martin Nguyen, D. Lorusso
223	Our experience of laparoscopic surgery in treatment of early cervical cancer patients: case series study and 5-year survival results.	Ukr Journ Radiol Oncol. 2025; 33(1):129-142. DOI: https://doi.org/10.46879/ukroj.1.2025.129-142	14	V. Sukhin , Yu. Shen, Yu. Moiseyenko, N. Fedorenko, N. Shchyt, H. Shen
224	SUCCOR 10 Years: A Decade's Perspective on Radical Hysterectomy Outcomes in Cervical Cancer.	Int J Gynecol Cancer. 2025 May;35(5):101690. https://doi.org/10.1016/j.ijgc.2025.101690 PMID: 40055121 IF 4.5	12	N. Manzour, L. Chiva, V. Zanagnolo, M. E. Căpîlna, N. Bizzarri, C. H. Mom, ... V. Sukhin ,...et al.
225	Implementing Image-Guided Brachytherapy (IGBT) For Cervical Cancer in Resource-Limited Settings: A Multicentre Workflow Impact Analysis from 14 Global Centres.	Radiother&Oncol. 2025. Vol.206, Suppl.1. S269-270. Abstr book ESTRO 2025 https://user-swndwmf.cld.bz/ESTRO-2025-Abstract-Book/276/	2	S. Ndarukwa, V. Hande, N. Aliyeva, A. Shami, B. Jaksic, E. Vanchinbazar, Ch. Batyrkanova, Eu. Gamboa, J. Flores, Ju. Mwaisilega, M. Sucharski, S. Majjaoui, S. Alanyali, S. Citonje, V. Sukhin , Ya. Anacak, D. Berger, A. Polo, S. Chopra
226	Time to next treatment by age subgroup in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.	ESMO Open 2025. Vol. 10, Suppl. S5 ESMO Gynaecological Cancers Congress Vienna, Austria, 19-21 June 2025 https://www.sciencedirect.com/journal/esmo-open/vol/10/suppl/S5 https://doi.org/10.1016/j.esmoop.2025.105175	1	I. Cass, J. Herrstedt, A. Jackson, V.S. Sukhin , L. Gilbert, A. Alvarez Secord, G. Ronzino, L. Willmott, O. Zub, L.M. Landrum, C. Lundgren, K. Schneider, M. Callahan, P. Nowicki, R. Miller, R. Gogoi, G. Antony, L. Austin, M.A. Powell, M.R. Mirza

227	Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.	Gynecol Oncol. 2025 Jun 30;199:88-95. https://doi.org/10.1016/j.ygyno.2025.06.003 PMID: 40592026. IF 4.5	8	Randall L, Xiang Y, Matsumoto T, Giannarelli D, Milla DP, Lopez KA, Acevedo A, Vizkeleti J, Salani R, Nogueira-Rodrigues A, Mejia FC, Korach J, Akilli H, Lee JY, Saevets VV, Samouelian V, Sehouli J, Tharavichikul E, Sukhin V , Colombo N, Chang CL, Cueva JF, Lalondrelle S, Petru E, Szamreta E, Nguyen AM, Yamada K, Li K, Pignata S, Lorusso D.
228	Analysis of the current state of the problem of treating early stages of cervical cancer as a basis for creating a research database.	Ukr Journ Radiol Oncol. 2025;33(2), 248-269. https://doi.org/10.46879/ukroj.2.2025.248-269	21	Radzishevskaya Y., Sukhina O., Vasylyev L., Sukhin V., Nemaltsova K., Radzishevskaya Y.

VII. Thesis and dissertation

1.	Preoperative radiochemotherapy with fluoropyrimidines (fp) in combined treatment of cervical cancer.	Thesis of dissertation (PhD). 14.01.23 – radiology, radiation therapy. Kharkiv. – 2009. – 26 p.	26	Sukhin V.S.
2.	Preoperative radiochemotherapy with fluoropyrimidines (fp) in combined treatment of cervical cancer.	Manuscript of dissertation (PhD). 14.01.23 – radiology, radiation therapy. Kharkiv. – 2009. – 169 p.	169	Sukhin V.S.
3.	Principles and justification of the individualization of uterine sarcoma treatment.	Thesis of dissertation (Doctor of Science). 14.01.07 – Oncology. Kharkiv. – 2018. – 42 p.	42	Sukhin V.S.
4.	Principles and justification of the individualization of uterine sarcoma treatment.	Manuscript of dissertation (Doctor of Science). 14.01.07 – Oncology. Kharkiv. – 2018. – 362 p.	362	Sukhin V.S.

VIII. Participation in the study working group, co-authorship / SCOPUS

1	European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.	<u>Ann Oncol. -2022; 33:3. 276-287.</u> http://doi.org/10.1016/j.annonc.2021.11.013	12	Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza MR, Brasiuniene B, Madry R, Brenton JD, Aulsems MGEM, Büttner R, Lambrechts D; European experts' consensus group:... Sukhin V., et al.
2	SUCCOR Risk: Design and Validation of a Recurrence	<u>Ann Surg Oncol. -2022; 29:4819–</u>	11	Manzour N, Chiva L, Chacón E, Martín-Calvo N, Boria F, Minguéz JA, Alcazar JL;

	Prediction Index for Early-Stage Cervical Cancer	4829. http://doi.org/10.1245/s10434-022-11671-5		SUCCOR Study Group: Zanagnolo V.,... Sukhin V. ,...et al.
3	Prognostic factors in undifferentiated uterine sarcoma: a subanalysis of the SARCUT study.	Arch Gyn & Obst. 2023. 308, 981–988. https://doi.org/10.1007/s00404-023-07057-x	8	R. Macuks, Y.Yildirim R. Mancari, P. Achimas-Cadariu, Th. K. Madhuri, E. Ortega, M. R. Mallmann, I. Zapardiel, SARCUT Study collaborative group:... Sukhin V. ,... et al.
4	SUCCOR nodes: may sentinel node biopsy determine the need for adjuvant treatment?	Ann Surg Oncol. 2023; 30, 4975–4985. https://doi.org/10.1245/s10434-023-13529-w .	11	B.Gómez A, Martín-Calvo N, Boria F, Manzour N, Chacón E, Bizzarri N, Chiva L; SUCCOR Study Group:... Sukhin V. ,...et al.
5	Influence of clinical and surgical factors on uterine carcinosarcoma survival	Cancers. 2023, 15(5), 1463-1473. https://doi.org/10.3390/cancers15051463	11	M. Gracia, Yu. Yildirim, R. Macuks, R. Mancari, P. Achimas-Cadariu, S. Polterauer, S. Iacoponi, I. Zapardiel, on behalf of SARCUT Study Group:... Sukhin V. ,...et al.
6	Lymph node dissection in uterine leiomyosarcomas: a matched-pair study.	Gynecol Oncol. 2023. 3;174:28-33. https://doi.org/10.1016/j.ygyno.2023.04.007 .	6	Coronado PJ, Alonso-Espias M, Yildirim Y, Macuks R, Mancari R, Achimas-Cadariu P, Anierte SM, Mitidieri M, Lambaudie E, Dubois N, Zapardiel I; SARCUT Study Group:... Sukhin V. ,...et al.
7	Dostarlimab for primary advanced or recurrent endometrial cancer.	N Engl J Med. 2023; 8;388(23):2145-2158. https://doi.org/10.1056/NEJMoa2216334	14	Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanks LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators: ... Sukhin V. ,...et al.
8	Impact of Hospital Case Volume on Uterine Sarcoma Prognosis: SARCUT Study Subanalysis.	Ann Surg Oncol 2023 Nov;30(12):7645-7652. http://doi.org/10.1245/s10434-023-13826-4 PMID: 37460742	8	Gorostidi M, Yildirim Y, Macuks R, Mancari R, Achimas-Cadariu P, Ibañez E, Corrado G, Bartusevicius A, Sukhina O, Zapardiel I; <i>SARCUT Study Group</i> :... Sukhin V. ,...et al.
9	Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.	N Engl J Med. 2023 Dec 7;389(23):2162-2174. http://doi.org/10.1056/NEJMoa2309169 PMID: 38055253.	13	Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic

				Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups: ... Sukhin V.,... et al.
10	Impact of perioperative characteristics on the recurrence risk and survival of patients with uterine leiomyosarcoma.	Int J Gyn Obstet. 2023 Dec;163(3):868-874. http://doi.org/10.1002/ijgo.14998 PMID: 37485666.	7	Gracia M, Yildirim Y, Macuks R, Mancari R, Achimas-Cadariu P, Cusine-Lopez L, Novak Z, Dallaku K, Zapardiel I; SARCUT Study Group: ... : ... Sukhin V.,... et al.